Publications

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2023)

The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts

Grams ME. et al, (2023), Journal of the American Society of Nephrology : JASN, 34, 482 - 494

Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery

Wijesurendra RS. et al, (2023)

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.

Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801

Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults.

Aguilar-Ramirez D. et al, (2022), Commun Med (Lond), 2

Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.

Gaziano L. et al, (2022), Circulation

Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.

Sandercock PAG. et al, (2022), Trials, 23

Evaluation of S/F94 as a proxy for COVID-19 severity

Swets MC. et al, (2022)

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.

Staplin N. et al, (2022), Hypertension

Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes.

Grams ME. et al, (2022), Diabetes Care, 45, 2055 - 2063

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329

Allocated but not treated: the silent 16% - Authors' reply.

Horby P. et al, (2022), Lancet, 399, 1775 - 1776

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

RECOVERY Collaborative Group None. et al, (2022)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151

Cookies on this website

Publications